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COPDAbstract Background: Deﬁciency of mannose-binding lectin (MBL) was claimed to increase sus-
ceptibility to and chronicity of microbial infections in different body systems. Tobacco smoking was
also claimed to be associated with reduced blood levels of MBL in blood and defective efferocytosis
in the airways. Both effects of smoking may be responsible for development of COPD in smokers
and for frequent exacerbations in patients who get COPD.
Aim: The aim of this study was to evaluate MBL in blood of smokers with and without COPD.
Methods: The study included 70 subjects, classiﬁed into two groups; 35 smokers without COPD
(group I: divided into 2 subgroups; 17 subjects mild to moderates smokers – group IA, and 18 heavy
smoker subjects – group IB). 35 smokers with COPD (group II) also divided into 2 subgroups: 17
subjects with mild to moderate disease (group IIA) and 18 subjects severe to very severe disease
(group IIB) according to GOLD (2013) [7] criteria. 20 healthy nonsmoker subjects were also
included as a control group (group III). Blood levels of MBL (measured by ELISA) were recorded.
Results: Levels of MBL were signiﬁcantly higher in nonsmoker than smoker groups and in
smokers without COPD than in those with it. Also a signiﬁcant inverse relation was found between
smoking index and MBL levels and a direct relation between it and FEV1%. These results indicate
that smoking reduces levels of MBL and its deﬁciency might contribute to development of COPD in
smokers.
Conclusion: Levels of MBL decrease in smokers with and without COPD and this might play a
role in the pathogenesis of lung inﬂammation in smokers with and without COPD.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.Introduction
Cigarette smoking is the second major cause of death in the
world. It is currently responsible for the death of one in ten
adults worldwide (about 5 million deaths each year). If currentd.
388 M.M. Naguib et al.smoking patterns continue, it will cause 10 million deaths each
year by 2020 according to WHO statistics [4]. Chronic
Obstructive Pulmonary Disease (COPD) is a common prevent-
able and treatable disease. It is characterized by persistent air-
ﬂow limitation that is usually progressive and associated with
an enhanced chronic inﬂammatory response in the airways and
the lung to noxious particles or gases [7].
Encouragement of smoking cessation is a critical compo-
nent of COPD management; however, once COPD is estab-
lished, cessation alone will not completely reverse
inﬂammation in the lung [8]. Thus there is an urgent need
for a better understanding of the mechanisms that underlie
the inﬂammatory effects of cigarette smoke in the lung and
for the development of treatment strategies that can modulate
these effects [9].
Mannose-binding lectin (MBL), also called mannose bind-
ing protein (MBP), is a calcium-dependent serum protein that
plays a role in the innate immune response by binding to car-
bohydrates on the surface of a wide range of pathogens
(viruses, bacteria, fungi and protozoa) where it can activate
the complement system or acts directly as an opsonin by tag-
ging the surface of a pathogen to facilitate recognition and
ingestion by phagocytes [14]. MBL helps proper efferocytosis
(phagocytosis of apoptotic cells) so its deﬁciency has the
potential to perpetuate airway inﬂammation in smokers via
secondary necrosis [24]. Mannose-binding lectin (MBL), in
addition to its traditionally recognized role in mediating host
defense by facilitating macrophage phagocytosis of pathogens,
is now recognized to regulate the clearance of apoptotic cells
[18]. Low levels of mannose binding lectin (MBL) have been
associated with increased susceptibility to infection and poor
prognosis in COPD patients [6].
Subjects, materials and methods
Subjects
This study was carried out 90 subjects, 70 cigarette smokers
and 20 apparently healthy subjects. 35 of smokers were
COPD patients attending the Mansoura Chest Hospital
(group I) and the other 35 smokers were without COPD
(group II). Patients were further divided into 2 subgroups:
mild to moderate (17; IA) and severe to very severe (18;
IB). Healthy smokers were also divided into 2 subgroups:
mild to moderate group (17; IIA) and heavy smokers group
(18; IIB). The 20 apparently healthy nonsmokers were taken
as a control group (group III) and were selected from volun-
teers and patients’ relatives.
Inclusion criteria
Smokers and COPD patients were diagnosed according to
GOLD [7] criteria in a stable condition and not in
exacerbation.
Exclusion criteria
(Due to possible effects on lung function and/or MBL levels):
1. Presence of respiratory diseases other than COPD.2. Any other co-morbidity (Systemic debilitating diseases as
renal or hepatic impairment and inﬂammatory disorders
as collagen vascular diseases).
3. Use of systemic anti-inﬂammatory drugs.
All subjects were submitted to the following:
1. History taking.
2. Clinical examination both general and local.
3. Complete blood count, liver function tests, kidney function
tests and erythrocyte sedimentation rate to conﬁrm inclu-
sion and exclusion criteria.
4. Radiological examination: Plain X-ray chest P-A view.
5. Pulmonary function tests (spirometry) before and after
bronchodilatation.
6. MBL in blood measured by ELISA:
Blood samples were collected by vein puncture into plain
tubes. Sera were obtained by centrifugation at 1000g for
5 min at room temperature. The samples were stored at 70
until analysis [20]. Serum mannose binding-lectin level was
measured with a solid phase sandwich enzyme-linked immuno-
sorbent assay (ELISA) using mannose-binding lectin ELISA
kit (Human MBL ELISA Kit Assay, Biotechnology Company,
CA 94089, USA).
Results
Majority of studied subjects were between 40 and 60 years as
well as the majority of smokers were males. In group III (con-
trol) numbers of males and females were equal. Smoking index
was higher in group IB (heavy smokers) and group IIB (severe
COPD) than group IA (mild smokers) and group IIA (mild
COPD) (Table 1).
FEV1% was signiﬁcantly higher in group III (control) and
group IA (mild smokers) than group IB (heavy smokers) and
group II (COPD groups), while FEF25–75% was signiﬁcantly
higher in group III (control) and group IA (mild smokers) than
group IB (heavy smokers) and group II (COPD groups)
(Table 2).
Levels of MBL were 23.60 ± 1.75 pg/ml in group III (con-
trol), 16.76 ± 3.10 pg/ml in group IA (mild to moderate smok-
ers without COPD), 4.15 ± 1.57 pg/ml in group IB (heavy
smokers without COPD), 2.78 ± 1.14 pg/ml in group IIA
(mild to moderate COPD) and 2.78 ± 1.14 pg/ml in group
IIB (severe to very severe COPD) (Table 3).
Mannose-binding lectin was signiﬁcantly higher in group
III (nonsmokers) than group I and group II (smokers groups)
and in group I (smokers) than group II (COPD). It was also
signiﬁcantly higher in group IA (Mild smokers) than group
IB (heavy smokers) and in group IIA (mild COPD) than group
IIB (severe COPD) (Table 4) as well as in females than males in
the control group (Table 5).
No signiﬁcant relation was seen between age and MBL in
all groups. Although the relation is not signiﬁcant yet it was
direct in group IA (mild smokers) and group IIB (severe
COPD) and inverse with other groups (Table 6). A signiﬁcant
inverse relation was found between smoking index and man-
nose-binding lectin in group I and II (all smokers) while no sig-
niﬁcant relation was observed in group III (control) or other
subgroups (Table 7, Figs. 1 and 2). The relation between
Table 1 Clinical characteristics of all groups included in the study.
Groups NO Age Mean ± SD Sex SI
M F
Group III 20 44.20 ± 5.26 10 10
Group IA 17 49.82 ± 5.98 15 2 259.41 ± 70.40
Group IB 18 52.22 ± 6.88 17 1 535.56 ± 121.18
Group IIA 17 49.24 ± 6.66 14 3 330.00 ± 64.32
Group IIB 18 57.17 ± 5.49 16 2 603.89 ± 87.52
SI = Smoking index, M=Male, F = Female.
Table 2 Comparison of FEV1%, and FEF25–75% among studied groups.
Groups No. FEV1% (Mean ± SD) F P
Group III 20 87.95 ± 5.34 85.122 <0.001*
Group IA 17 76.65 ± 11.68
Group IB 18 60.94 ± 10.80
Group IIA 17 57.47 ± 8.24
Group IIB 18 35.67 ± 9.63
FEF25–75% (Mean ± SD) 136.969 <0.001*
Group III 20 84.70 ± 5.49
Group IA 17 70.12 ± 11.04
Group IB 18 55.61 ± 8.58
Group IIA 17 39.18 ± 12.07
Group IIB 18 20.28 ± 8.62
Table 3 Descriptive statistics of mannose-binding lectin (MBL) (pg/ml) in all studied groups.
Groups No. MBL (Mean ± SD) in pg/ml F P
Group III 20 23.60 ± 1.75 542.525 <0.001*
Group IA 17 16.76 ± 3.10
Group IB 18 4.15 ± 1.57
Group IIA 17 2.78 ± 1.14
Group IIB 18 1.02 ± 1.01
Table 4 Comparison of MBL (pg/ml) among different studied groups.
t P
MBL Group III (n= 20) Mean ± SD Group I and Group II (n= 70) Mean ± SD
23.60 ± 1.75 6.08 ± 6.47 20.234 <0.001*
MBL Group I (n= 35) Mean ± SD Group II (n= 35) Mean ± SD
10.28 ± 6.83 1.87 ± 1.39 7.132 <0.001*
MBL Group IA (n= 17) Mean ± SD Group IB (n= 18) Mean ± SD
16.76 ± 3.10 4.15 ± 1.57 15.075 <0.001*
MBL Group IIA (n= 17) Mean ± SD Group IIB (n= 18) Mean ± SD
2.78 ± 1.14 1.02 ± 1.01 4.858 <0.001*
Table 5 Comparison of MBL (pg/ml) between males and females in all studied groups.
MBL (pg/ml) Males Females t P
No. Mean ± SD No. Mean ± SD
Group III 10 22.44 ± 1.34 10 24.76 ± 1.28 3.956 0.001*
Group II 32 10.13 ± 6.96 3 11.80 ± 6.29 0.399 0.693
Group I 30 1.80 ± 1.41 5 2.34 ± 1.24 0.807 0.425
Study of mannose-binding lectin in smokers with and without COPD 389
Table 6 Correlation between age and MBL (pg/ml) in studied
groups.
Age MBL (pg/ml)
R P
Group I and II 0.246 0.040
Group III 0.017 0.943
Group IA 0.004 0.987
Group IB 0.247 0.324
Group IIA 0.391 0.121
Group IIB 0.369 0.132
Table 7 Correlation between smoking index and MBL (pg/
ml) in studied groups.
Smoking index MBL (pg/ml)
R P
Group I and II 0.621 <0.001
Group IA 0.133 0.610
Group IB 0.636 0.005
Group IIA 0.101 0.699
Group IIB 0.131 0.604
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Figure 1 Correlation between smoking index and MBL (pg/ml)
in group I and II (all smokers).
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Figure 2 Correlation between smoking index and MBL (pg/ml)
in group IB (heavy smokers).
Table 8 Correlation between FEV1% and MBL (pg/ml) in
studied groups.
FEV1% MBL (pg/ml)
R P
Group I & II 0.707 <0.001*
Group III 0.288 0.218
Group IA 0.334 0.190
Group IB 0.156 0.538
Group IIA 0.079 0.764
Group IIB 0.252 0.312
MBL (pg/ml)
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Figure 3 Correlation between FEV1% and MBL (pg/ml) in
group I and II (all smokers).
390 M.M. Naguib et al.MBL and FEV1% was signiﬁcant and direct in group I and II
(all smokers) while no signiﬁcant relation was observed in
group III (control) or other subgroups (Table 8, Figs. 3 and
4). Correlation between MBL and FEF25–75% was similar
to that with FEV1% (Table 9, Figs. 5 and 6).
Discussion
Cigarette smoke contains an extremely high concentration of
oxidants, which induce inﬂammation in the lung and its air-
ways and contribute to accumulation of apoptotic material
and secondary necrosis of the uncleared material and
perpetuation of chronic airway inﬂammation. Impairment of
phagocytosis of bacteria in smokers is due to decreased levelsof mannose-binding lectin (MBL) and correlated with effero-
cytosis in smokers and COPD patients and also correlated
with COPD disease severity [3].
This study aimed at evaluation of MBL in blood of smok-
ers with and without COPD and its relation to airway
function.
Although patients were selected randomly, yet all of them
were above 40 years of age indicating that COPD is common
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Figure 4 Correlation between FEV1% and MBL (pg/ml) in
group III (control).
Table 9 Correlation between FEF25–75% and MBL (pg/ml)
in studied groups.
FEF25–75% MBL (pg/ml)
R P
Group I and II 0.722 <0.001*
Group III 0.098 0.680
Group IA 0.059 0.822
Group IB 0.510 <0.001*
Group IIA 0.065 0.804
Group IIB 0.023 0.928
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Figure 5 Correlation between FEF25–75% and MBL (pg/ml) in
group I and II (all smokers).
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Figure 6 Correlation between FEF25–75% and MBL (pg/ml) in
group IB (heavy smokers).
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patients were males (Table 1). These results agree with known
literature [17,12,7].
In this study ventilatory parameters (FEV1%, FEV1/
FVC% and FEF25–75%) were signiﬁcantly higher in controls
than COPD and in nonsmoker and mild smoker controls than
heavy smoker controls (Table 2). These results reﬂect the direct
effect of smoking on lung functions and are also welldocumented in the literature [7] with the decline in lung func-
tion was argued to chronic airway inﬂammation by cigarette
smoke [16]. Moreover, smoking cessation could reduce this
smoking-related precipitous decline in lung function [1] as
repeated attempts to quit smoking even with subsequent
relapses were found to prevent loss of lung function especially
in patients with mild COPD [2] and prolonged abstinence is
associated with reduction in pulmonary symptoms [13].
In this work severe COPD group and heavy smoker con-
trols showed a signiﬁcantly higher smoking index than mild
smoker controls and moderate COPD patients but this mainly
related to selection criteria of our patients and controls
(Table 1). Heavy smokers with smoking indices comparable
to that of severe COPD but without the disease indicate that
either such patient will later get into COPD as evidenced by
their lower ventilatory parameters than healthy nonsmokers
or that not only tobacco smoking is responsible for COPD
but also other factors contribute [7].
In our study, values of MBL were signiﬁcantly higher in
control and mild smoker groups than heavy smoker and
COPD groups and signiﬁcantly higher in nonsmoker groups
than smoker groups and in smokers without COPD than in
those with it (p< 0.001 for all; Tables 3 and 4). Also MBL
was signiﬁcantly higher in mild smoker than heavy smoker
groups without COPD and was signiﬁcantly higher in mild
than severe COPD group (p< 0.001 for both). This means
that smoking is associated with lower levels of MBL and that
such lower levels in smokers may contribute to development of
COPD. It has been shown that efferocytosis has a protective
effect against inﬂammation and protects cytoskeleton struc-
tures and that MBL improves this process, hence, defective
efferocytosis will occur in smokers with low MBL levels in
addition to airway inﬂammation and remodeling [11].
Contrary to our results [5] found no association between
MBL and COPD or its severity a ﬁnding that does not agree
with that of Hodge et al. [11] where levels of MBL were found
to be low in airway of COPD patients even in the presence of
infection and levels correlated with efferocytosis.
In our ﬁndings, MBL was signiﬁcantly higher in females
than males in controls but not in other groups (Table 5).
Higher levels of MBL in females than in males may contribute
to the lower incidence of COPD in them and also possibly
392 M.M. Naguib et al.related to the higher rate of smoking and occupational expo-
sure to pollution in men [15].
In the present study no signiﬁcant relation was seen
between age and MBL in all groups. Although the relation
was not signiﬁcant yet it was direct in mild smokers and severe
COPD patients and inverse with other groups (Table 6). Age
by itself does not appear to affect level of MBL but alterations
in its genome can do through production of aberrant mole-
cules with reduced function despite normal levels [22].
In the present study a signiﬁcant inverse relation between
smoking index and mannose-binding lectin in smokers as a
whole and in heavy smoker groups (p< 0.001) was observed,
while no signiﬁcant relation was observed in controls or mild
smoker subgroups (Table 7). This result is in agreement with
the study done by Hodge et al. [10] who investigated the
potential effect of cigarette smoke in the airway by measuring
MBL in the lungs of smoker and COPD groups. To ascertain
whether MBL levels are restored by cessation of cigarette
smoking in the absence of COPD, they further studied a
group of healthy ex-smokers. Also the authors evaluated
MBL as a potential novel therapy for smoking-related lung
inﬂammation. They investigated the ability of MBL to
improve efferocytosis and reduce inﬂammation in vivo and
found that levels of MBL were signiﬁcantly decreased in
BAL from subjects with COPD versus never-smoker control
subjects.
Healthy smokers and ex-smokers with normal lung func-
tion showed a signiﬁcant reduction in MBL levels compared
with never-smoker controls while no signiﬁcant difference
was seen between ex-smokers and controls. This means that
the level of smoking adversely affects MBL levels and this
effect could play a role in the development of COPD. Contrary
to our results, Ulutas et al. [23] found higher levels of MBL in
smokers than controls and MBL levels correlated directly to
smoking index. Also the authors found no relation between
COPD and MBL and advised for larger studies to spot light
on the role of this protein in the development of COPD. Oli-
vo-Marston et al. [19] studied the relation between passive
smoking in children, MBL and development of lung cancer.
They found children exposed to tobacco smoke to have high
levels of MBL with gene mutation and levels correlated with
severity of exposure to smoke and risk of lung cancer
development.
In our work a signiﬁcant direct relation between both of
FEV1% predicted and FEF25–75% and MBL in smokers
and COPD subgroups was found (Tables 8 and 9, Figs. 12–
23). Being protective against pulmonary infections, it was
expected for MBL to be directly proportional to lung function
in all groups especially in COPD patients. This may be
explained by the larger number of all smoker group than sub-
groups. Some studies showed MBL to be not related to smok-
ing status or lung function loss in COPD [23]. Also, Eagans
et al. [5] found no relation between MBL and different COPD
variables.
Being a function of small airways, the relation of FEF25–
75% to MBL reﬂects a protective effect of the molecule; in
other words heavy smokers with low MBL levels are at
increased risk of small airway disease. Small airways are clin-
ically silent until greatly affected. Again, absence of a signiﬁ-
cant relation between MBL and FEV1% and FEF25–75% in
smokers and COPD patients shown by Ulutas et al. [23] in
part disagree with our results. On the other hand, nebulizedadministration of MBL to smoke exposed mice reversed the
dysfunction of both alveolar and lung tissue macrophages
and reduced airway inﬂammation evidenced by a signiﬁcant
reduction in WBC and macrophage numbers to near normal
levels which supports our results [11].
Although we found no relation between lung functions and
MBL in COPD yet, the available data do support human
in vivo studies of MBL therapy in COPD. Both plasma-
derived (pdMBL) MBL and recombinant (rMBL) have been
produced and studied for potential immunotherapeutic bene-
ﬁts. Plasma-derived MBL is superior to rMBL when compar-
ing the key biological processes central to MBL function
including mannose-binding and complement deposition
in vivo [21]. Furthermore, exposing alveolar macrophages
in vitro to MBL at clinically achievable concentrations resulted
in a signiﬁcant increase in phagocytic ability. Plasma-derived
MBL may thus prove to be a useful adjunct therapeutic
strategy for COPD and other chronic lung diseases where
MBL may play a pathophysiological role and clinical trials
are warranted [10].
Conclusion
MBL levels decrease in smokers with and without COPD and
have an inverse relation with smoking severity (index) and a
direct one with spirometric parameters meaning that MBL
might have a role in the pathogenesis of lung inﬂammation
in smokers with and without COPD.
Conﬂict of interest
There is no Conﬂict of interest.References
[1] N.R. Anthonisen, J.E. Connett, J.P. Kiley, M.D. Altose, W.C.
Bailey, A.S. Buist, et al, Effects of smoking intervention and the
use of an inhaled anticholinergic bronchodilator on the rate of
decline of FEV1. The Lung Health Study, JAMA 272 (19)
(1994) 1497–1505.
[2] N.R. Anthonisen, M.A. Skeans, R.A. Wise, J. Manfreda, R.E.
Kanner, J.E. Connett, et al, The effects of smoking cessation
intervention on 14.5 year mortality: a randomized clinical trial,
Ann. Intern. Med. 142 (4) (2005) 233–239.
[3] J.S. Brody, A. Spira, Chronic obstructive pulmonary disease,
inﬂammation and lung cancer, Proc. Am. Thorac. Soc. 3 (2006)
535–538.
[4] R. Doll, R. Peto, K. Wheathy, R. Gray, I. Sutherl, Mortality in
relation to smoking: 40 years observations on male British
doctors, Br. Med. J. 309 (1994) 901–911.
[5] T.M.L. Eagans, P. Aukrust, P.S. Bakke, et al, Systemic
mannose-binding lectin is not associated with chronic
obstructive pulmonary disease, Respir. Med. 104 (2010) 283–
290.
[6] D.P. Eisen, M.M. Dean, P. Thomas, P. Marshall, N. Gerns, S.
Heatley, et al, Low mannose-binding lectin function is
associated with sepsis in adult patients, FEMS Immunol. Med.
Microbiol. 48 (2006) 274–282.
[7] Global Initiative for Chronic Obstructive Lung Disease. (2013):
Global strategy for the diagnosis, management and prevention
of chronic obstructive pulmonary disease. NHLBI/WHO
Global Initiative for Chronic Obstructive Lung Disease
(GOLD). Available at: www.goldcopd.org.
Study of mannose-binding lectin in smokers with and without COPD 393[8] S. Hodge, G.L. Hodge, R. Scicchitano, P.N. Reynolds, M.
Holmes, Alveolar macrophages from subjects with chronic
obstructive pulmonary disease are deﬁcient in their ability to
phagocytes apoptotic airway epithelial cells, Immunol. Cell Biol.
81 (2003) 289–296.
[9] S. Hodge, G.L. Hodge, S.T. Brozyna, H.P.A. Jersmann, M.D.
Holmes, P.N. Reynolds, Azithromycin increases phagocytosis of
apoptotic airway epithelial cells by alveolar macrophages
in vitro, Eur. Respir. J. 28 (2006) 486–495.
[10] S. Hodge, G.L. Hodge, H. Jersmann, J. Ahern, M. Holmes, P.N.
Reynolds, Azithromycin improves macrophage phagocytic
function and expression of mannose receptor in chronic
obstructive pulmonary disease, Am. J. Respir. Crit. Care Med.
178 (2008) 139–148.
[11] S. Hodge, G. Matthews, M.M. Dean, J. Ahern, M. Djukic,
et al, Therapeutic role for mannose binding lectin in cigarette
smoke-induced lung inﬂammation? Evidence from a murine
model, Am. J. Respir. Cell Mol. Biol. 178 (2) (2010) 139–148.
[12] K. Ito, P.J. Barnes, COPD as a disease of accelerated lung aging,
Chest J. 13 (2009) 173–180.
[13] R.E. Kanner, N.R. Anthonisen, J.E. Connett, Lower respiratory
illnesses promote FEV1decline in current smokers but not ex-
smokers with mild chronic obstructive pulmonary disease.
Results from the Lung Health Study, Am. J. Respir. Crit.
Care Med. 164 (2001) 358–364.
[14] A. Koch, M. Melbye, P. Sørensen, P. Homøe, H.O. Madsen, K.
Mølbak, C.H. Hansen, et al, Acute respiratory tract infections
and mannose-binding lectin insufﬁciency during early
childhood, JAMA 285 (10) (2001) 1316–1321.
[15] O.P. Kurmi, S. Semple, P. Simkhada, W.C. Smith, J.G. Ayres,
COPD and chronic bronchitis risk of indoor air pollution from
solid fuel: a systematic review and meta-analysis, Thorax 65 (3)
(2010) 221–228.
[16] T. Lapperre, L. Willems, W. Timens, W. Timens, K. Rabe, P.
Hiemstra, et al, Small airways dysfunction and neutrophilicinﬂammation in bronchial biopsies and BAL in COPD, Chest
131 (2007) 53–59.
[17] A.M. Menezes, R. Perez-Padilla, J.R. Jardim, A. Muino, M.V.
Lopez, G. Valvidia, et al, COPD in ﬁve latin American cities
(The PLATINO study): prevalence study, Lancet 366 (2005)
1875–1881.
[18] C.A. Ogden, A. de Cathelineau, P.R. Hoffmann, D. Bratton, B.
Ghebrehiwet, V.A. Fadok, P.M. Henson, C1q and mannose
binding lectin engagement of cell surface calreticulin and CD91
initiates macropinocytosis and uptake of apoptotic cells, J. Exp.
Med. 194 (2001) 781.
[19] S.E. Olivo-Marston, P. Yang, L.E. Mechanic, et al, Childhood
exposure to secondhand smoke and functional mannose binding
lectin polymorphisms are associated with increased lung cancer
risk, Cancer Epidemiol. Biomarkers Prev. 18 (12) (2009) 3375–
3383.
[20] R. Pincus, A. McPherson, Henry’s Clinical Diagnosis and
Management by Laboratory Methods, 22, Elsevier Saunders,
2011, p. 30–34.
[21] R. Rajagopalan, V.P. Salvi, J.C. Jensenius, N. Rawal, Human
mannan-binding lectin and its variants, Immunol. Lett. 123
(2009) 114–124.
[22] K. Takahashi, R.A. Ezekowitz, The role of the mannose binding
lectin in innate immunity, Clin. Infect. Dis. 41 (7) (2005) 440–
444.
[23] G.S. Ulutas, T. Fatma, Aylin Ozgen Alpaydın, C. C¸etinkaya, C.
Ulman, Yesim Gu¨venc¸, et al, Mannose binding lectin (MBL)
gene polymorphism and relationship between serum MBL
concentrations in COPD patients, Turk. J. Biochem. 37 (1)
(2012) 87–93.
[24] R.W. Vandivier, P.M. Henson, I.S. Douglas, Burying the
dead: the impact of failed apoptotic cell removal
(efferocytosis) on chronic inﬂammatory lung disease, Chest
129 (2006) 1673–1682.
